[Effect of flunisolide on exacerbation of clinical symptoms, spirometric parameters, consumption of B2-adrenergic drugs and levels of cortisol and ECP in serum of patients with bronchial asthma].
The effects of flunisolide on a symptoms, spirometry, beta 2-agonist consumption, serum cortisol and ECP levels in 30 asthmatics were assessed. The patients qualified for the study after a two week run--in period, inhaled flunisolide from MDI--1000 micrograms daily (2 x 2 puffs) for a period of 4 weeks. Patients noted daily asthma symptoms, morning and evening PEF, the beta 2-agonists consumption and side effects in their diary cards. Each patient had 3 visits to the clinic, before and after the run-in period and at the end of the study. During the visits spirometry were performed. After the flunisolide therapy, statistically significant decreases in the daily and nightly asthma symptoms, diurnal variations of PEF, beta 2-agonist consumption, serum ECP levels and increases in morning and evening PEF and in serum cortisol levels. The patients tolerated the drug well. No serious side effects were observed during the study.